Javascript must be enabled to continue!
Monitoring the Efficacy of Iodine‐131‐MIBG Therapy using Fluorine‐18‐FDG‐PET
View through CrossRef
Summary: Background: The purpose of this study was to assess the potential of fluorine‐18 fluoro‐2‐deoxy‐d‐glucose positron emission tomography (18F‐FDG‐PET) for monitoring the efficacy of iodine‐131 metaiodobenzylguanidine (131I‐MIBG) therapy in neuroendocrine tumours.Methods: A total of seven 131I‐MIBG therapies with 3.7 to 10.2 GBq were carried out in three patients suffering respectively from a phaeochromocytoma, a paraganglioma and a metastatic neuroendocrine tumour of an unknown primary. The post‐therapeutic whole‐body scintigrams were compared with the results of six 18F‐FDG‐PET studies performed at the time of the therapies. One patient received three PET scans prior to each one of the MIBG therapies, and one patient was studied twice.Results: 18F‐FDG uptake in tumour sites seemed to correlate well with tumour differentiation, showing no uptake in one patient with a highly differentiated neuroendocrine tumour, and moderate‐to‐intense uptake in the two other patients with metastatic disease. Those tumour sites that had a simultaneous positive uptake in both the MIBG scintigram and the PET scan showed response to therapy as a continuous reduction in MIBG uptake over time. They also showed a qualitative decrease in FDG accumulation during the follow‐up. This was associated with a decrease in the mean and maximum standard uptake values of more than 50 % in some metastases, while the X‐ray computed tomography showed no decrease in tumour volume. Two patients revealed additional metastases that were unknown on the basis of prior diagnostic or therapeutic PET scans and radiological follow‐up.Conclusions: It may be concluded from these cases that 18F‐FDG‐PET is a valuable tool for an initial metabolic staging of neuroendocrine tumours prior to 131I‐MIBG therapy, as it can reveal tumour sites beyond the reach of radioisotope therapy. It may also be of importance in assessing therapeutic potential in those tumour sites that do show positive MIBG uptake.
Title: Monitoring the Efficacy of Iodine‐131‐MIBG Therapy using Fluorine‐18‐FDG‐PET
Description:
Summary: Background: The purpose of this study was to assess the potential of fluorine‐18 fluoro‐2‐deoxy‐d‐glucose positron emission tomography (18F‐FDG‐PET) for monitoring the efficacy of iodine‐131 metaiodobenzylguanidine (131I‐MIBG) therapy in neuroendocrine tumours.
Methods: A total of seven 131I‐MIBG therapies with 3.
7 to 10.
2 GBq were carried out in three patients suffering respectively from a phaeochromocytoma, a paraganglioma and a metastatic neuroendocrine tumour of an unknown primary.
The post‐therapeutic whole‐body scintigrams were compared with the results of six 18F‐FDG‐PET studies performed at the time of the therapies.
One patient received three PET scans prior to each one of the MIBG therapies, and one patient was studied twice.
Results: 18F‐FDG uptake in tumour sites seemed to correlate well with tumour differentiation, showing no uptake in one patient with a highly differentiated neuroendocrine tumour, and moderate‐to‐intense uptake in the two other patients with metastatic disease.
Those tumour sites that had a simultaneous positive uptake in both the MIBG scintigram and the PET scan showed response to therapy as a continuous reduction in MIBG uptake over time.
They also showed a qualitative decrease in FDG accumulation during the follow‐up.
This was associated with a decrease in the mean and maximum standard uptake values of more than 50 % in some metastases, while the X‐ray computed tomography showed no decrease in tumour volume.
Two patients revealed additional metastases that were unknown on the basis of prior diagnostic or therapeutic PET scans and radiological follow‐up.
Conclusions: It may be concluded from these cases that 18F‐FDG‐PET is a valuable tool for an initial metabolic staging of neuroendocrine tumours prior to 131I‐MIBG therapy, as it can reveal tumour sites beyond the reach of radioisotope therapy.
It may also be of importance in assessing therapeutic potential in those tumour sites that do show positive MIBG uptake.
Related Results
The Halogens
The Halogens
AbstractThe halogens are those elements in group XVII of the periodic table, and include fluorine, chlorine, bromine, iodine, and astatine, the latter of which is a radioactive ele...
Baseline Staging Evaluation in Lymphoma: The Role of FDG PET, CT, and Bone Marrow Biopsy
Baseline Staging Evaluation in Lymphoma: The Role of FDG PET, CT, and Bone Marrow Biopsy
Abstract
Abstract 2640
BACKGROUND:
The revised response criteria for malignant lymphoma (Cheson et al JCO 25:579 ...
Semi-Quantitative Evaluation of Pre-Transplant FDG-PET in Relapsed and Refractory Hodgkin Lymphoma
Semi-Quantitative Evaluation of Pre-Transplant FDG-PET in Relapsed and Refractory Hodgkin Lymphoma
Abstract
Abstract 2015
Introduction:
We previously reported the prognostic impact of pre-transplant functional im...
Diagnostic Use of Post-therapy 131I-Meta-Iodobenzylguanidine Scintigraphy in Consolidation Therapy for Children with High-Risk Neuroblastoma
Diagnostic Use of Post-therapy 131I-Meta-Iodobenzylguanidine Scintigraphy in Consolidation Therapy for Children with High-Risk Neuroblastoma
123I-meta-iodobenzylguanidine (123I-mIBG) scintigraphy is used for evaluating disease extent in children with neuroblastoma. 131I-mIBG therapy has been used for evaluation in child...
SEMANA DE ENFERMAGEM E SEUS ASPECTOS SOCIAIS NA VALORIZAÇÃO PROFISSIONAL: UM RELATO DE EXPERIÊNCIA DO GRUPO PET-ENFERMAGEM
SEMANA DE ENFERMAGEM E SEUS ASPECTOS SOCIAIS NA VALORIZAÇÃO PROFISSIONAL: UM RELATO DE EXPERIÊNCIA DO GRUPO PET-ENFERMAGEM
A enfermagem é o pilar da assistência pois está na linha de frente do cuidado holístico, todavia esta é estigmatizada e desvalorizada, assim como não possui reconhecimento consider...
Clinical and 18F-FDG PET/CT Imaging Characteristics of Post-radiotherapy Sacral Insufficiency Fractures in Cervical Cancer Patients
Clinical and 18F-FDG PET/CT Imaging Characteristics of Post-radiotherapy Sacral Insufficiency Fractures in Cervical Cancer Patients
Introduction:
Sacral Insufficiency Fractures (SIFs) are a common yet frequently misdiagnosed late complication following pelvic radiotherapy for cervical
cancer...
Urinary iodine concentration: a biochemical parameter for assessing the iodine status
Urinary iodine concentration: a biochemical parameter for assessing the iodine status
Iodine is a micronutrient, which is essential for the synthesis of thyroid hormones. Thyroid hormones play a major role in the development of different functional components in dif...
Forced diuresis and dual-phase 18F-fluorodeoxyglucose-PET/CT scan for restaging of urinary bladder cancers
Forced diuresis and dual-phase 18F-fluorodeoxyglucose-PET/CT scan for restaging of urinary bladder cancers
Abstract
Context: The results of 18 F-fluorodeoxyglucose (FDG)-PET imaging carried out with the current standard techniques for assessment of urinary tract cancers have...

